0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Non Invasive Prenatal Testing"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Australia Non-Invasive Prenatal Testing Market 2025 - 2033 - Product Thumbnail Image

Australia Non-Invasive Prenatal Testing Market 2025 - 2033

  • Report
  • February 2025
  • 70 Pages
  • Australia
From
EUR$735USDGBP
EUR$1,050USDGBP
From
EUR$699USDGBP
EUR$999USDGBP
From
EUR$735USDGBP
EUR$1,050USDGBP
From
EUR$769USDGBP
EUR$1,099USDGBP
From
EUR$693USDGBP
EUR$990USDGBP
From
EUR$1,750USDGBP
EUR$2,500USDGBP
From
EUR$4,500USDGBP
From
EUR$4,500USDGBP
From
EUR$3,500USDGBP
From
EUR$3,500USDGBP
From
EUR$3,500USDGBP
From
EUR$4,500USDGBP
From
EUR$3,500USDGBP
From
EUR$4,750USDGBP
Loading Indicator

Non-invasive prenatal testing (NIPT) is a type of prenatal screening used to detect chromosomal abnormalities in a fetus. It is a safe and accurate method of testing that does not involve any risk to the mother or fetus. NIPT is typically used to detect Down syndrome, trisomy 18, and trisomy 13, as well as other chromosomal abnormalities. It is also used to determine the sex of the fetus. NIPT is becoming increasingly popular as an alternative to traditional invasive prenatal testing, such as amniocentesis and chorionic villus sampling. NIPT is offered by a variety of diagnostic companies, including Illumina, Natera, Ariosa Diagnostics, and Sequenom. These companies provide a range of services, from laboratory testing to genetic counseling. They also offer a variety of testing options, such as single-gene tests, whole-genome sequencing, and targeted sequencing. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more